Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Surveillance of Complex Renal Cysts - The SOCRATIC Study

NCT04558593 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2021-02-02
Last updated
2026-06-01

Condition(s) studied

Complex Renal Cyst

Investigational drug(s) / intervention(s)

Active surveillanceSurgery

Active surveillance: Per standard of care: Imaging and blood tests every 6 months (3 first years) and annually (following years)

Surgery: Per standard of care: partial or full resection of the kidney, imaging annually

Study summary

One third of individuals aged \>60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic safety of this strategy for patients with Bosniak III/IV cysts.

This is an multicenter prospective observational longitudinal study. The main objective is to compare the 5-year follow-up cancer-specific survival between the active surveillance and the surgical groups.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years old and older; * diagnosed with a Bosniak III or IV cyst (classification 2019); * size of cystic component ≤7cm; * cyst wall/septum nodule (obtuse margin of protrusion) \<10mm (perpendicular axis) or nodular/solid component ≤2 cm in any axis; * life expectancy \>5 years (by physician's estimate); * new diagnosis ≤ 12 months from accrual date; * currently asymptomatic from the disease; * deemed fit enough for surgery; * willingness and ability to complete questionnaires in either French or English; * able and willing to provide informed consent Exclusion Criteria: * history of a hereditary renal cancer syndrome; * presence of polycystic kidney disease; * any prior history of RCC; * received systemic therapy for another malignancy within the 12 months prior to accrual; * uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction/unstable angina within 6 months that would predispose to immediate surgical therapy; * metastatic disease or evidence of vascular or nodal disease; * unwillingness to undergo monitoring and imaging studies; * any contra-indication(s) to contrast-enhanced imaging (estimated glomerular filtration rate \<30min/mL)

Primary outcome measure(s)

  • 5-year cancer-specific survival — from the date of enrollment (defined by signed consent) to the end of follow-up (up to 5 years)
    Defined as kidney cancer survival 5 years after the enrollment

Trial sites (18)

FacilityCityRegionStatus
Prostate Cancer Center Calgary Alberta Recruiting
Northern Alberta Urology Center Edmonton Alberta Recruiting
Vancouver Prostate Centre Vancouver British Columbia Recruiting
Mens Health Clinic Winnipeg Manitoba Recruiting
Nova Scotia Health Authority Halifax Nova Scotia Recruiting
St-Joseph's Hospital Hamilton Ontario Recruiting
The Ottawa Hospital Ottawa Ontario Recruiting
Thunder Bay Health Sciences Center Thunder Bay Ontario Recruiting
Princess Margaret Hospital Toronto Ontario Recruiting
Woodstock hospital Woodstock Ontario Recruiting
Centre intégré de santé et de services sociaux de Chaudière-Appalaches - Hôtel-Dieu de Lévis Lévis Quebec Recruiting
CHUM Montreal Quebec Recruiting
Hôpital Maisonneuve-Rosemont (CISSS-EIMtl) Montreal Quebec Recruiting
McGill University Health Centre Montreal Quebec Recruiting
CHU de Québec - Université Laval Québec Quebec Recruiting
Centre de recherche du Centre hospitalier Universitaire de Sherbrooke Sherbrooke Quebec Recruiting
CIUSSS Mauricie-Centre-du-Québec Trois-Rivières Quebec Recruiting
CHU Bordeaux (URO-CCR) Bordeaux France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04558593 on ClinicalTrials.gov ↗ ← All trials in France